How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comA Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
Description:
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.
Phase:
Phase 1/2
Contacts:
Ruofei Tong (CONTACT)ruofei.tong@btyy.com
+86-18002098164
Wei Fan (PRINCIPAL_INVESTIGATOR) Rui Dong (CONTACT)rui.dong@btyy.com
+8613158775185
Yan Yang (STUDY_DIRECTOR)Government Study Link:
NCT07249892 - Click here to see study onClinicalTrials.gov
Share your feedback
Help us improve your experience